Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.

Article  PubMed  Google Scholar 

Srivastava S, Mohanty A, Nam A, Singhal S, Salgia R. Chemokines and NSCLC: emerging role in prognosis, heterogeneity, and therapeutics. Semin Cancer Biol. 2022;86:233–46.

Article  CAS  PubMed  Google Scholar 

Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023;22:40.

Article  PubMed  PubMed Central  Google Scholar 

Qian F, Yang W, Chen Q, Zhang X, Han B. Screening for early stage lung cancer and its correlation with lung nodule detection. J Thorac Dis. 2018;10:S846–59.

Article  PubMed  PubMed Central  Google Scholar 

Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. NCCN Guidelines® insights: non–small cell lung cancer, version 2.2023: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2023;21:340–50.

Article  CAS  Google Scholar 

Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27:1345–56.

Article  CAS  PubMed  Google Scholar 

Wu F, Fan J, He Y, Xiong A, Yu J, Li Y, et al. Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. Nat Commun. 2021;12:2540.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Piechotta V, Jakob T, Langer P, Monsef I, Scheid C, Estcourt LJ, et al. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with transplant‐ineligible multiple myeloma: a network meta‐analysis. Cochrane Database Syst Rev. 2019;2019:CD013487.

PubMed  PubMed Central  Google Scholar 

Lee JM, McNamee CJ, Toloza E, Negrao MV, Lin J, Shum E, et al. Neoadjuvant targeted therapy in resectable NSCLC: current and future perspectives. J Thorac Oncol. 2023;18:1458–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bi H-L, Zhang X-L, Zhang Y-L, Xie X, Xia Y-L, Du J, et al. The deubiquitinase UCHL1 regulates cardiac hypertrophy by stabilizing epidermal growth factor receptor. Sci Adv. 2020;6:eaax4826.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li S, Song Y, Wang K, Liu G, Dong X, Yang F, et al. USP32 deubiquitinase: cellular functions, regulatory mechanisms, and potential as a cancer therapy target. Cell Death Discov. 2023;9:338.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Q, Ye C, Tian T, Jiang Q, Zhao P, Wang X, et al. The emerging role of ubiquitin-specific protease 20 in tumorigenesis and cancer therapeutics. Cell Death Dis. 2022;13:434.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paulding CA, Ruvolo M, Haber DA. The Tre2 (USP6) oncogene is a hominoid-specific gene. Proc Natl Acad Sci USA. 2003;100:2507–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun Y-L, Guan X-L, Zhang P, Li M-F, Zhang J, Sun L. Pol-miR-363-3p plays a significant role in the immune defense of Japanese flounder Paralichthys olivaceus against bacterial and viral infection. Fish Shellfish Immunol. 2020;104:439–46.

Article  CAS  PubMed  Google Scholar 

Sapmaz A, Berlin I, Bos E, Wijdeven RH, Janssen H, Konietzny R, et al. USP32 regulates late endosomal transport and recycling through deubiquitylation of Rab7. Nat Commun. 2019;10:1454.

Article  PubMed  PubMed Central  Google Scholar 

Hertel A, Alves LM, Dutz H, Tascher G, Bonn F, Kaulich M, et al. USP32-regulated LAMTOR1 ubiquitination impacts mTORC1 activation and autophagy induction. Cell Rep. 2022;41:111653.

Article  CAS  PubMed  Google Scholar 

Pankratz N, Dumitriu A, Hetrick KN, Sun M, Latourelle JC, Wilk JB, et al. Copy number variation in familial Parkinson disease. PLoS ONE. 2011;6:e20988.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma Y, Tian S, He S, Chen Q, Wang Z, Xiao X, et al. The mechanism of action of FXR1P-related miR-19b-3p in SH-SY5Y. Gene. 2016;588:62–8.

Article  CAS  PubMed  Google Scholar 

Jeong S, Oh JM, Oh K-H, Kim I-W. Differentially expressed miR-3680-5p is associated with parathyroid hormone regulation in peritoneal dialysis patients. PLoS ONE. 2017;12:e0170535.

Article  PubMed  PubMed Central  Google Scholar 

Nakae A, Kodama M, Okamoto T, Tokunaga M, Shimura H, Hashimoto K, et al. Ubiquitin specific peptidase 32 acts as an oncogene in epithelial ovarian cancer by deubiquitylating farnesyl-diphosphate farnesyltransferase 1. Biochem Biophys Res Commun. 2021;552:120–7.

Article  CAS  PubMed  Google Scholar 

Hu W, Wei H, Li K, Li P, Lin J, Feng R. Downregulation of USP32 inhibits cell proliferation, migration and invasion in human small cell lung cancer. Cell Prolif. 2017;50:e12343.

Article  PubMed  PubMed Central  Google Scholar 

Chen S, Chen X, Li Z, Mao J, Jiang W, Zhu Z, et al. Identification of ubiquitin-specific protease 32 as an oncogene in glioblastoma and the underlying mechanisms. Sci Rep. 2022;12:6445.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li J, Bo Y, Ding B, Wang L. Understanding the regulatory role of USP32 and SHMT2 in the progression of gastric cancer. Cell J. 2023;25:222–8.

PubMed  PubMed Central  Google Scholar 

Akhavantabasi S, Akman HB, Sapmaz A, Keller J, Petty EM, Erson AE. USP32 is an active, membrane-bound ubiquitin protease overexpressed in breast cancers. Mamm Genome. 2010;21:388–97.

Article  CAS  PubMed  Google Scholar 

Zhang H, Tao Y, Ding X, Wang Y, Wang X. Roles of the hsa_circ_0013880/USP32/Rap1b axis in the proliferation and apoptosis of acute myeloid leukemia cells. Acta Biochim Biophys Sin (Shanghai). 2023;55:382–93.

Article  CAS  PubMed  Google Scholar 

Liu C, Chen Z, Fang M, Qiao Y. MicroRNA let-7a inhibits proliferation of breast cancer cell by downregulating USP32 expression. Transl Cancer Res. 2019;8:1763–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li C, Gao Z, Cui Z, Liu Z, Bian Y, Sun H, et al. Deubiquitylation of Rab35 by USP32 promotes the transmission of imatinib resistance by enhancing exosome secretion in gastrointestinal stromal tumours. Oncogene. 2023;42:894–910.

Article  CAS  PubMed  Google Scholar 

Kirk JA, Cheung JY, Feldman AM. Therapeutic targeting of BAG3: considering its complexity in cancer and heart disease. J Clin Invest. 2021;131:e149415.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yuan Y, Jiang J-Y, Wang J-M, Sun J, Li C, Liu B-Q, et al. BAG3-positive pancreatic stellate cells promote migration and invasion of pancreatic ductal adenocarcinoma. J Cell Mol Med. 2019;23:5006–16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Behl C. Breaking BAG: the co-chaperone BAG3 in health and disease. Trends Pharm Sci. 2016;37:672–88.